They may not discuss adverse effects, product sourcing, dosing uncertainty, interactions, contraindications, or whether treatment is legally available through proper medical channels
What We Know So Far The two-day meeting was convened by the FDA's Pharmacy Compounding Advisory Committee, which was recently overhauled with many new members who have ties to the peptide industry, according to NPR
Caserta D, Di Benedetto L, Bordi G, DAmbrosio A, Moscarini M
We get these two questions often, which is why they also appear on our FAQ page
NAD+ must be administered with a separate syringe and at a different site because its acidic solution can degrade the KLOW peptides on contact